BVT Discount Zert BIIB 28.06.2024/ DE000VM5US62 /
5/24/2024 8:36:53 AM | Chg.+0.21 | Bid9:59:39 PM | Ask9:59:39 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
173.64EUR | +0.12% | - Bid Size: - |
- Ask Size: - |
Biogen Inc | - USD | 6/28/2024 | Call |
GlobeNewswire
3:00 AM
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Again...
GlobeNewswire
2:18 AM
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against...
GlobeNewswire
5/24
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class ...
GlobeNewswire
5/24
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...
GlobeNewswire
5/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Con...
GlobeNewswire
5/23
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...
GlobeNewswire
5/23
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Sub...
GlobeNewswire
5/22
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
5/16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
5/15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
5/9
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
5/8
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
5/7
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
4/29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
4/25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...